Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as compared to small molecule generics remain limited.
Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not a privilege but a right. The government should understand this.
In a seminal work, former military officers Lt. Gen. D.S. Hooda & Lt. Col. Pavithran Rajan put forth a framework to approach cognitive warfare, called Socio-Technical-Cognitive Battlespace.
India, China and Russia share more contradictions than congruence. Each has a different worldview, as also a different adversary. The rude fact is that BRICS is the most irrelevant of all such groupings.
COMMENTS